Please ensure Javascript is enabled for purposes of website accessibility

Why Translate Bio Crashed 21% Today

By Todd Campbell – Jun 26, 2020 at 4:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage vaccine developer, which is working on a COVID-19 vaccine candidate, announced it's selling more shares to the public.

What happened

After the company announced the pricing of a planned $125 million secondary stock offering, shares of Translate Bio (TBIO) tumbled 21% on Friday.

So what

In collaboration with biopharma giant Sanofi (SNY -2.31%), Translate Bio has been investigating mRNA vaccine candidates for COVID-19 since March. On Tuesday, the companies announced they're expanding their relationship, with Translate Bio receiving upfront money, potential milestone payments, and royalties on future net sales in exchange for exclusive commercial rights to multiple vaccine candidates.

An up trending arrow begins to trend down.


Specifically, Translate Bio is pocketing $425 million up front -- $300 million in cash and $125 million from shares it's selling to Sanofi at $25.59 per share. It can receive up to $1.9 billion more by hitting clinical, regulatory, and commercial milestones, including $450 million from prior collaborations with Sanofi. Sanofi also agreed to pay tiered royalties on sales. However, the companies didn't disclose the exact percentages of those royalty payments.

News of the expanded relationship sparked a significant rally in the biotech's shares this week, prompting management to announce a secondary stock offering to further bolster its balance sheet. Today, the market learned management will offer 12.5 million shares at $22 per share, including 6.8 million shares being sold by Takeda's Shire Human Genetic Therapies, an existing shareholder. Translate Bio won't make any money from Shire's shares, but it estimates it will receive $125 million, before fees, from the offering. 

Now what

Translate Bio's mRNA approach is similar to that of Moderna (MRNA -0.37%), which already has its SARS-CoV-2 vaccine in phase 2 trials. The strategy is to tinker with our genetic code in a way that makes our cells create specific proteins that are also expressed by the novel coronavirus, allowing the body to develop antibodies to it. 

Although Moderna is further along in the development timeline, Translate Bio believes it can have a vaccine in clinical trials in the fourth quarter, and generate data that could conceivably lead to a Food and Drug Administration approval sometime in 2021. The additional cash provided by the Sanofi deal and secondary offering should give it the financial resources necessary to execute on that goal, but there's no guarantee that its efforts will pan out.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Translate Bio, Inc. Stock Quote
Translate Bio, Inc.
Sanofi Stock Quote
$38.90 (-2.31%) $0.92
Moderna, Inc. Stock Quote
Moderna, Inc.
$125.15 (-0.37%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.